Loading news...
biote (NASDAQ: BTMD - Get Free Report) and Agilent Technologies (NYSE: A - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations. Profitability This table compares biote and Agilent Technologies' net
Bandera Partners LLC decreased its position in shares of biote Corp. (NASDAQ: BTMD) by 6.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,283,791 shares of the company's stock after selling 151,844 shares during the period. biote accounts for 4.1%
biote Corp. ( BTMD ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Bret Christensen - CEO & Director Robert Peterson - CFO and Chief Business Officer Conference Call Participants Szymon Serowiecki Kaumil Gajrawala - Jefferies LLC, Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Jeff Van Sinderen - B. Riley Securities, Inc., Research Division Jungwon Kim - TD Cowen, Research Division George Kelly - ROTH Capital Partners, LLC, Research Division Presentation Operator Good day, and welcome to the Biote Third Quarter 2025 Earnings Conference Call.
biote Corp. (BTMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.33 per share a year ago.
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the third quarter ended September 30, 2025. “When we undertook our organizational restructuring in May, we identified three strategic priorities: accelerate growth from new providers, maximize value from our top-tier clinics, and improve our financial performance through gre.
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call m.
I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company's vertical integration, digital platform growth, and improved cost controls are driving margin expansion and long-term profitability potential. Restructuring aims to accelerate provider wins, deepen practitioner relationships, and boost financial discipline, though it has led to lower 2025 guidance.
biote Corp. (NASDAQ:BTMD ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Bret Christensen - CEO & Director Robert C. Peterson - Chief Financial Officer Conference Call Participants Jeffrey Wallin Van Sinderen - B.
biote Corp. (BTMD) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.14 per share a year ago.
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2025. “Consistent with our action plan to drive structural and cultural change, Biote initiated an organizational restructuring in early May designed to strengthen our business and position us for increased and sustainable profitable.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
IRVING, Texas--(BUSINESS WIRE)--biote Corp.(NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. “We are pleased to welcome Rich Barrera to Biote's Board of Directors,” said Marc Beer, Executive Chairman of Biote. “Rich has a distinguished background as an investment professional, founding R.
biote Corp. (NASDAQ:BTMD ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Szymon Serowiecki - Investor Relations Bret Christensen - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Conference Call Participants Kaumil Gajrawala - Jefferies Les Sulewski - Truist Jonna Kim - TD Cowen Jeff Van Sinderen - B. Riley George Kelly - ROTH Capital Partners Operator Hello, and welcome to the biote First Quarter 2025 Earnings Conference Call.
Biote Corp. (BTMD) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.23 per share a year ago.
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that several members of its Board of Directors, along with CEO Bret Christensen, have made open market purchases of Biote's common stock, acquiring an aggregate of approximately 260,000 shares. Marc Beer, Biote Executive Chairman, said, "These share purchase.
biote Corp. (NASDAQ:BTMD ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Corporate Participants Szymon Serowiecki - Investor Relations Mark Beard - Executive Chairman Bret Christensen - Chief Executive Officer Bob Peterson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Jeff Van Sinderen - B. Riley George Kelly - ROTH Capital Partners Alex Fuhrman - Craig-Hallum Capital Group Operator Good day, and welcome to the Biote Fourth Quarter 2024 Earnings Conference Call.
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 12, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conf.
Here is how biote Corp. (BTMD) and Doximity (DOCS) have performed compared to their sector so far this year.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The mean of analysts' price targets for biote Corp. (BTMD) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.